OTC Markets OTCPK - Delayed Quote USD

Medios AG (MEDOF)

50.00
0.00
(0.00%)
At close: May 7 at 4:00:00 PM EDT
Loading Chart for MEDOF
  • Previous Close 0.00
  • Open 13.64
  • Bid 11.30 x 38800
  • Ask 16.30 x 36200
  • Day's Range 13.64 - 13.64
  • 52 Week Range 13.64 - 50.00
  • Volume 2,000
  • Avg. Volume 0
  • Market Cap (intraday) 1.275B
  • Beta (5Y Monthly) 1.20
  • PE Ratio (TTM) 73.53
  • EPS (TTM) 0.68
  • Earnings Date May 13, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Medios AG, together with its subsidiaries, supplies specialty pharmaceutical drugs primarily in Germany. It operates through Pharmaceutical Supply and Patient-Specific Therapies segments. The Pharmaceutical Supply segment offers products on oncology, neurology, autoimmunology, ophthalmology, infectiology, and hemophilia diseases. The Patient-Specific Therapies segment manufactures medications for patients on behalf of pharmacies. This segment includes cytostatic infusion preparations, antibody therapies, virostatic and antibiotic medications, parenteral nutrition solutions, and investigational medicinal products. Medios AG was founded in 2016 and is headquartered in Berlin, Germany.

www.medios.ag

472

Full Time Employees

December 31

Fiscal Year Ends

Recent News: MEDOF

View More

Performance Overview: MEDOF

Trailing total returns as of 5/8/2025, which may include dividends or other distributions. Benchmark is DAX P (^GDAXI) .

YTD Return

MEDOF
0.00%
DAX P (^GDAXI)
17.30%

1-Year Return

MEDOF
0.00%
DAX P (^GDAXI)
26.24%

3-Year Return

MEDOF
0.00%
DAX P (^GDAXI)
70.78%

5-Year Return

MEDOF
0.00%
DAX P (^GDAXI)
114.16%

Compare To: MEDOF

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: MEDOF

View More

Valuation Measures

Annual
As of 5/7/2025
  • Market Cap

    355.80M

  • Enterprise Value

    505.92M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    --

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.67%

  • Return on Assets (ttm)

    2.81%

  • Return on Equity (ttm)

    2.56%

  • Revenue (ttm)

    1.88B

  • Net Income Avi to Common (ttm)

    12.55M

  • Diluted EPS (ttm)

    0.68

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    106M

  • Total Debt/Equity (mrq)

    46.94%

  • Levered Free Cash Flow (ttm)

    59.02M

Research Analysis: MEDOF

View More

Company Insights: MEDOF

Research Reports: MEDOF

View More

People Also Watch